Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Recurrent Ovarian Carcinoma
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Approximately 330 patients will be randomized in a 1:1 ration to the treatments specified below: Arm A - Platinum-based chemotherapy according to investigator's discretion Arm B - Pegylated liposomal doxorubicin 30 mg/m² + Trabectedin 1.1 mg/m² (q3w)
Approximately 330 patients will be randomized in a 1:1 ration to the treatments specified below: Arm A - Platinum-based chemotherapy according to investigator's discretion Arm B - Pegylated liposomal doxorubicin 30 mg/m² + Trabectedin 1.1 mg/m² (q3w)
Tracking Information
- NCT #
- NCT03690739
- Collaborators
- Not Provided
- Investigators
- Study Chair: Felix Hilpert, MD, PhD Mammazentrum am Krankenhaus Jerusalem, Hamburg
Get Well Soon